RXI: Phase 1 testing of scar-reduction drug successful
Marlborough-based RXi Pharmaceuticals Corp. , announced Friday what it called successful results of initial testing of its anti-dermal scarring drug, RXI-109, in monkeys, as part of a dose-range finding study to build the company’s ophthalmology business.
RXI-109 targets connective tissue growth factor (CTGF), a gene that can reduce or inhibit scar formation following surgery.
"These remarkable results constitute a major boost to the value of our newly formed ophthalmology franchise," President and CEO Geert Cauwenbergh said in a statement. "This finding opens up an avenue to possibly develop topical forms of RXI-109 to combat corneal scarring which often occurs secondary to trauma or infection and can lead to visual impairment, including blindness."
The company said that two Phase 2 clinical trials are underway to evaluate the effectiveness and safety of RXI-109 on outcomes resulting from lower abdominal surgeries and to evaluate the effectiveness and safety in healthy subjects who undergo elective surgical excisions of two similarly sized and placed scars.
WBJ Web Partners
Most Recent
Most Recent
0 Comments